PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) Current Ratio
- Current ratio · latest quarter: Value 25.05×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 25.05× | Current assets / current liabilities. $292.01M ÷ $11.66M ≈ 25.05× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 292.01M USD | Assets, Current |
| Current obligations | 11.66M USD | Liabilities, Current |
| Cash and equivalents | 288.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 1.94M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $292.01M | $11.66M | $288.19M | (m) | (m) | (m) | $1.94M | (m) | 25.05× |
| 2026-03-31 | $339.20M | $32.52M | $329.46M | (m) | (m) | (m) | $4.30M | (m) | 10.43× |
| 2025-12-31 | $315.19M | $40.84M | $307.53M | (m) | (m) | (m) | $5.88M | (m) | 7.72× |
| 2025-09-30 | $339.97M | $51.44M | $330.84M | (m) | (m) | (m) | $10.50M | (m) | 6.61× |
| 2025-06-30 | $385.48M | $67.81M | $371.44M | (m) | (m) | (m) | $12.20M | (m) | 5.68× |
| 2025-03-31 | $436.17M | $48.46M | $417.94M | (m) | (m) | (m) | $16.03M | (m) | 9.00× |
| 2024-12-31 | $485.41M | $48.50M | $471.39M | (m) | (m) | (m) | $7.77M | (m) | 10.01× |
| 2024-09-30 | $534.98M | $46.42M | $519.26M | (m) | $0.00 | (m) | $10.33M | (m) | 11.52× |
| 2024-06-30 | $585.98M | $46.74M | $564.12M | (m) | $0.00 | (m) | $9.29M | (m) | 12.54× |
| 2024-03-31 | $565.87M | $43.27M | $546.51M | (m) | $0.00 | (m) | $14.42M | (m) | 13.08× |
| 2023-12-31 | $639.28M | $56.89M | $618.83M | (m) | $5.16M | (m) | $25.39M | (m) | 11.24× |
| 2023-09-30 | $690.60M | $53.37M | $670.90M | (m) | $5.16M | (m) | $19.46M | (m) | 12.94× |
| 2023-06-30 | $677.10M | $71.56M | $659.11M | (m) | $524.00K | (m) | $13.85M | (m) | 9.46× |
| 2023-03-31 | $700.34M | $48.88M | $686.18M | (m) | (m) | (m) | $12.52M | (m) | 14.33× |
| 2022-12-31 | $719.10M | $50.15M | $710.41M | (m) | $0.00 | (m) | $9.27M | (m) | 14.34× |
| 2022-09-30 | $524.56M | $50.60M | $495.63M | (m) | (m) | (m) | $9.79M | (m) | 10.37× |
| 2022-06-30 | $521.29M | $40.11M | $508.80M | (m) | (m) | (m) | $7.55M | (m) | 13.00× |
| 2022-03-31 | $555.62M | $36.50M | $542.99M | (m) | (m) | (m) | $9.32M | (m) | 15.22× |
| 2021-12-31 | $584.81M | $33.45M | $579.09M | (m) | (m) | (m) | $3.69M | (m) | 17.48× |
| 2021-09-30 | $607.53M | $29.20M | $600.10M | (m) | $79.00K | (m) | $3.48M | (m) | 20.81× |
| 2021-06-30 | $409.47M | $52.90M | $399.83M | (m) | $3.00K | (m) | $5.91M | (m) | 7.74× |
| 2021-03-31 | $352.30M | $23.46M | $342.99M | (m) | $1.00K | (m) | $4.21M | (m) | 15.02× |
| 2020-12-31 | $299.28M | $25.85M | $295.38M | (m) | $15.00K | (m) | $4.12M | (m) | 11.58× |
| 2020-09-30 | $320.49M | $21.72M | $314.52M | (m) | $22.00K | (m) | $2.81M | (m) | 14.75× |
| 2020-06-30 | $341.12M | $18.54M | $333.94M | (m) | $56.00K | (m) | $2.12M | (m) | 18.40× |
| 2020-03-31 | $359.69M | $17.09M | $352.69M | (m) | $174.00K | (m) | $3.30M | (m) | 21.05× |
| 2019-12-31 | $378.38M | $17.71M | $375.72M | (m) | $68.00K | (m) | $1.24M | (m) | 21.36× |
| 2019-09-30 | $409.20M | $31.76M | $390.30M | (m) | (m) | (m) | $2.42M | (m) | 12.88× |
| 2019-06-30 | $418.71M | $28.02M | $398.14M | (m) | (m) | (m) | $1.52M | (m) | 14.95× |
| 2019-03-31 | $415.19M | $14.91M | $410.11M | (m) | (m) | (m) | $2.10M | (m) | 27.85× |
| 2018-12-31 | $431.39M | $14.93M | $427.66M | (m) | $2.00K | (m) | $1.47M | (m) | 28.90× |
| 2018-09-30 | $456.91M | $23.63M | $451.51M | (m) | $0.00 | (m) | $4.49M | (m) | 19.34× |
| 2018-06-30 | $494.04M | $46.13M | $486.21M | (m) | $8.00K | (m) | $10.05M | (m) | 10.71× |
| 2018-03-31 | $537.15M | $35.55M | $429.04M | (m) | $12.00K | (m) | $11.59M | (m) | 15.11× |
| 2017-12-31 | $426.33M | $37.37M | $417.62M | (m) | $240.00K | (m) | $13.63M | (m) | 11.41× |
| 2017-09-30 | $469.06M | $39.26M | $456.06M | (m) | $220.00K | (m) | $11.06M | (m) | 11.95× |
| 2017-06-30 | $511.72M | $39.60M | $471.73M | (m) | $30.24M | (m) | $12.54M | (m) | 12.92× |
| 2017-03-31 | $514.20M | $33.68M | $506.55M | (m) | $271.00K | (m) | $6.25M | (m) | 15.27× |
| 2016-12-31 | $391.36M | $41.08M | $386.92M | (m) | $178.00K | (m) | $13.07M | (m) | 9.53× |
| 2016-09-30 | $415.64M | $36.91M | $408.57M | (m) | $409.00K | (m) | $10.54M | (m) | 11.26× |
| 2016-06-30 | $450.60M | $33.46M | $442.95M | (m) | $364.00K | (m) | $11.59M | (m) | 13.47× |
| 2016-03-31 | $482.09M | $23.23M | $474.25M | (m) | $1.00M | (m) | $7.90M | (m) | 20.75× |
| 2015-12-31 | $377.40M | $22.22M | $370.59M | (m) | $509.00K | (m) | $4.52M | (m) | 16.99× |
| 2015-09-30 | $393.58M | $18.56M | $387.80M | (m) | $814.00K | (m) | $4.06M | (m) | 21.21× |
| 2015-06-30 | $406.20M | $13.46M | $402.39M | (m) | $961.00K | (m) | $2.87M | (m) | 30.19× |
| 2015-03-31 | $284.42M | $9.54M | $279.86M | (m) | $1.36M | (m) | $1.99M | (m) | 29.80× |
| 2014-12-31 | $299.11M | $12.04M | $293.58M | (m) | $1.73M | (m) | $4.72M | (m) | 24.84× |
| 2014-09-30 | $308.82M | $9.97M | $306.15M | (m) | $967.00K | (m) | $1.24M | (m) | 30.97× |
| 2014-06-30 | $307.02M | $11.31M | $303.85M | (m) | $1.49M | (m) | $1.48M | (m) | 27.14× |
| 2014-03-31 | $199.60M | $8.96M | $195.05M | (m) | $2.16M | (m) | $2.13M | (m) | 22.27× |
| 2013-12-31 | $178.22M | $7.41M | $176.68M | (m) | $0.00 | (m) | $1.79M | (m) | 24.06× |
| 2013-09-30 | $102.94M | $7.71M | $101.86M | (m) | (m) | (m) | $896.00K | (m) | 13.34× |
| 2013-06-30 | $113.59M | $9.08M | $112.51M | (m) | (m) | (m) | $779.00K | (m) | 12.51× |
| 2013-03-31 | $120.79M | $5.09M | $119.56M | (m) | (m) | (m) | (m) | (m) | 23.75× |
| 2012-12-31 | $125.84M | $1.74M | $124.86M | (m) | (m) | (m) | $0.00 | (m) | 72.16× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |